Phase 3 trial of lampalizumab shows no benefit of treatment for late stage dry AMD.
The initial results of the first phase 3 trial of lampalizumab, an investigational treatment for geographic atrophy, the end stage of dry age-related macular degeneration, have just been released. Unfortunately, the study showed that lampalizumab, given as a series of injections into the eye, had no beneficial impact on the growth of the area of atrophy or cell death behind the macula in people with late stage dry AMD. This result was surprising given that an earlier phase 2 study suggested a beneficial effect, at least in some people.
There had been great hope for lampalizumab as potentially the first treatment to become available for dry AMD. However, this is a complex disease and there are many hurdles to overcome in the quest to find a treatment. Continued investment in research, both in Australia and across the world, is so vital in finding answers for this disease.
You can view the official media release at here
Information contained herein is accurate and reliable as at 11 September 2017.